Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 1, 2011, Pages 32-41

  Ho, Alan L ^a   Sherman, Eric ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BCL 2 inhibitors; Chronic lymphocytic leukemia; Immunomodulators; Monoclonal antibodies; Protein kinase inhibitors

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; AXITINIB; B RAF KINASE INHIBITOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; GEFITINIB; GSK 1120212; GSK 2118436; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MOTESANIB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLX 4032; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RADIOACTIVE IODINE; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN; XL 281;

ANAPLASTIC THYROID CANCER; BRAF GENE; BREAST CANCER; CANCER INCIDENCE; CANCER SURVIVAL; CENTRAL SEROUS RETINOPATHY; CEREBROVASCULAR ACCIDENT; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CUTANEOUS SQUAMOUS CELL CARCINOMA; DIARRHEA; DISTANT METASTASIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FOLLICULITIS; HEMATOLOGIC DISEASE; HUMAN; HURTHLE CELL CANCER; HYPERTENSION; KIDNEY CANCER; LIVER CANCER; LIVER FAILURE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; ONCOGENE; OVERALL SURVIVAL; PANCREAS CANCER; POINT MUTATION; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; CELL DIFFERENTIATION; HUMANS; MAP KINASE SIGNALING SYSTEM; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 79951472564     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892-2899.
3. Fagin JA, Tuttle RM, Pfister DG. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2621-2624.
4. Pfister DG, Fagin JA. Refractory thyroid cancer: a paradigm shift in treatment is not far off. J Clin Oncol. 2008;26:4701-4704.
5. Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol. 2009;21:296-303.
6. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457.
7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
8. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30:216-222.
9. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAF V600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65:4238-4245.
10. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28:742-762.
11. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93:3943-3949.
12. Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007;92:2840-2843.
13. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer. 2006;13:257-269.
14. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90: 6373-6379.
15. Leboeuf R, Baumgartner JE, Benezra M, et al. BRAF V600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab. 2008;93:2194-2201.
16. Liu D, Xing M. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid. 2008;18:853-864.
17. Ouyang B, Knauf JA, Smith EP, et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res. 2006;12:1785-1793.
18. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439:358-362.
19. Hong DS, Reddy SB, Prieto VG, et al. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol. 2008;144:779-782.
20. Lacouture ME, McArthur GA, Chapman PB, et al. PLX4032 (RG7204), a selective mutant RAF inhibitor: clinical and histologic characteristics of therapyassociated cutaneous neoplasms in a phase I trial. J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28(15 suppl):Abstract 8592.
21. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol. 2009;27:e59-e61.
22. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464: 431-435.
23. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140: 209-221.
24. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427-430.
25. Schwartz GK, Robertson S, Shen A, et al. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. J Clin Oncol (ASCO Annual Meeting Abstracts). 2009;27(15S):Abstract 3513.
26. Flaherty K, Puzanov I, Sosman J, et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2009;27(15S):Abstract 9000.
27. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28(15S):Abstract 8503.
28. Lucas AS, Cohen EE, Cohen RB, et al. Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements. J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28(15S):Abstract 5536
29. Infante JR, Fecher LA, Nallapareddy S, et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J Clin Oncol (Meeting Abstracts). 2010;28(15S):Abstract 2503.
30. Dhar DK, Kubota H, Kotoh T, et al. Tumor vascularity predicts recurrence in differentiated thyroid carcinoma. Am J Surg. 1998;176:442-447.
31. Ishiwata T, Iino Y, Takei H, Oyama T, Morishita Y. Tumor angiogenesis as an independent prognostic indicator in human papillary thyroid carcinoma. Oncol Rep. 1998;5:1343-1348.
32. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol. 1999;155:1967-1976.
33. Katoh R, Miyagi E, Kawaoi A, et al. Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. Hum Pathol. 1999;30:891-897.
34. Klein M, Picard E, Vignaud JM, et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol. 1999;161:41-49.
35. Soh EY, Duh QY, Sobhi SA, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab. 1997;82:3741-3747.
36. Viglietto G, Maglione D, Rambaldi M, et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene. 1995;11:1569-1579.
37. Viglietto G, Romano A, Manzo G, et al. Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene. 1997;15: 2687-2698.
38. Bauer AJ, Terrell R, Doniparthi NK, et al. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid. 2002;12:953-961.
39. Yu XM, Lo CY, Lam AK, Lang BH, Leung P, Luk JM. The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery. 2008;144:934-940; discussion 940-941.
40. Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:656-658.
41. Lennard CM, Patel A, Wilson J, et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery. 2001;129:552-558.
42. Belletti B, Ferraro P, Arra C, et al. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogene. 1999;18:4860-4869.
43. Bauer AJ, Patel A, Terrell R, et al. Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model. Ann Clin Lab Sci. 2003;33:192-199.
44. Soh EY, Eigelberger MS, Kim KJ, et al. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery. 2000; 128:1059-1065; discussion 1065-1056.
45. Hoffmann S, Burchert A, Wunderlich A, et al. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine. 2007;31:105-113.
46. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E, Eilles C. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology. 2004;145: 1031-1038.
47. Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol. 2007;88:271-277.
48. Vieira JM, Santos SC, Espadinha C, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol. 2005;153:701-709.
49. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714-4719.
50. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675-1684.
51. Capdevila J, Iglesias L, Halperin I, et al. Sorafenib in patients (pts) with advanced thyroid carcinoma (TC): a compassionate use program. J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28(7s):Abstract 5590.
52. Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009;161:923-931.
53. Nagaiah G, Fu P, Wasman JK, et al. Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC). J Clin Oncol (ASCO Annual Meeting Abstracts). 2009;27(15S):Abstract 6058.
54. Flaherty KT, Schiller J, Schuchter LM, et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res. 2008;14:4836-4842.
55. Brose MS, Troxel AB, Redlinger M, et al. Effect of BRAF V600E on response to sorafenib in advanced thyroid cancer patients. J Clin Oncol (ASCO Annual Meeting Abstracts). 2009;27(15S):Abstract 6002.
56. Cohen EE, Needles BM, Cullen KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26(15S):Abstract 6025.
57. Carr L, Goulart B, Martins R, et al. Phase II trial of continuous dosing of sunitinib in advanced, FDG-PET avid, medullary thyroid carcinoma (MTC) and well-differentiated thyroid cancer (WDTC). J Clin Oncol (ASCO Annual Meeting Abstracts). 2009;27(15S):Abstract 6056.
58. Ravaud A, de la Fouchardiere C, Courbon F, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26(15S):Abstract 6058.
59. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26:4708-4713.
60. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359:31-42.
61. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11:962-972.
62. Aasland R, Akslen LA, Varhaug JE, Lillehaug JR. Co-expression of the genes encoding transforming growth factor-alpha and its receptor in papillary carcinomas of the thyroid. Int J Cancer. 1990;46:382-387.
63. Schiff BA, McMurphy AB, Jasser SA, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res. 2004;10:8594-8602.
64. Lemoine NR, Wyllie FS, Lillehaug JR, et al. Absence of abnormalities of the c-erbB-1 and c-erbB-2 proto-oncogenes in human thyroid neoplasia. Eur J Cancer. 1990;26:777-779.
65. Mitsiades CS, Kotoula V, Poulaki V, et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab. 2006;91:3662-3666.
66. Akslen LA, Varhaug JE. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer. 1995;76:1643-1654.
67. Chen BK, Ohtsuki Y, Furihata M, et al. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int J Oncol. 1999;15:893-898.
68. Masago K, Asato R, Fujita S, et al. Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. Int J Cancer. 2009;124:2744-2749.
69. Elliott DD, Sherman SI, Busaidy NL, et al. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol. 2008;39:15-20.
70. Lee DH, Lee GK, Kong SY, et al. Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J Clin Pathol. 2007;60:881-884.
71. Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008;93:3106-3116.
72. Gabler B, Aicher T, Heiss P, Senekowitsch-Schmidtke R. Growth inhibition of human papillary thyroid carcinoma cells and multicellular spheroids by anti-EGFreceptor antibody. Anticancer Res. 1997;17:3157-3159.
73. Bergstrom JD, Westermark B, Heldin NE. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res. 2000;259:293-299.
74. Nobuhara Y, Onoda N, Yamashita Y, et al. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer. 2005;92:1110-1116.
75. Kim S, Schiff BA, Yigitbasi OG, et al. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther. 2005;4:632-640.
76. Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008;18:317-323.
77. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e17.
78. Han S-W, Kim T-Y, Jeon YK, et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-Ras mutation, and Akt phosphorylation. Clinical Cancer Research. 2006;12:2538-2544.
79. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705-5712.
80. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/ protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005;280:40406-40416.
81. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098-1101.
82. di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet. 1998;19:348-355.
83. Yeager N, Brewer C, Cai KQ, Xu XX, Di Cristofano A. Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium. Cancer Res. 2008;68:444-449.
84. Dahia PL, Marsh DJ, Zheng Z, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997; 57:4710-4713.
85. Saji M, Ringel MD. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol. 2010;321:20-28.
86. Garcia-Rostan G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65:10199-10207.
87. Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13:1161-1170.
88. Wu G, Mambo E, Guo Z, et al. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab. 2005;90:4688-4693.
89. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69:4885-4893.
90. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Aktdependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10:594-601.
91. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTENdeficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A. 2001; 98:10314-10319.
92. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A. 2001;98:10320-10325.
93. Liu D, Hou P, Liu Z, Wu G, Xing M. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res. 2009;69:7311-7319.
94. Brewer C, Yeager N, Di Cristofano A. Thyroid-stimulating hormone initiated proliferative signals converge in vivo on the mTOR kinase without activating AKT. Cancer Res. 2007;67:8002-8006.
95. Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther. 2007;82:381-388.